Remibrutinib
- Generic Name
- Remibrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H27F2N5O3
- CAS Number
- 1787294-07-8
- Unique Ingredient Identifier
- I7MVZ8HDNU
- Associated Conditions
- -
- Associated Therapies
- -
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT05432388
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Institute for Asthma and Allergy PC, Chevy Chase, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Phase 3
Recruiting
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05156281
- Locations
- 🇺🇸
New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Nova Clinical Research LLC, Bradenton, Florida, United States
🇺🇸Univ of Florida College of Medicine, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath